Videnskabelig årsrapport 2005 - Rigshospitalet

Finsencentret
Cand.vet., ph.d. Annemette Thougaard
Cand.vet., ph.d. Kamille Dumong
Petersen
Studenterforskere
Lise Lütgen Henriksen
Sisse Würtz
Rosa Zandi
Scholarstipendiat, stud. pharm. Susan
Hansen
Stud.scient. Alice Bjerregaard,
specialestuderende
Stud.scient. Rober Dagil,
specialestuderende
Thomas Tuxen Poulsen
Øvrigt forskningspersonale
Mette Willingshøj, bioanalytiker
Louise Bangsbo van Hauen,
laboratorietekniker
Pia Pedersen, bioanalytiker
Annette Nielsen, bioanalytiker
Mette Christiansen, bioanalytiker
Sanne Christiansen, bioanalytiker
Anita Johansen, dyrepasser
Vigtigste satsningsområder
inden for forskningen
Åndedrætstilpasset strålebehandling,
præcisionsstrålebehandling og
avanceret billeddannelse (specielt
PET/CT) i planlægning af
strålebehandling.
Genekspressionsanalyser af småcellet
lungecancer (GeneChip teknologi).
Cancerspecifik receptors (EGFRvIII) rolle
for udvikling af den maligne
fænotype.
Udvikling og eksperimentel afprøvning af
lipid-nanopartikler og
cancerspecifikke promotorer til
targeteret genterapi.
Publikationer
A. Førsteforfatter fra
forskningsenheden
Daugaard G, Lassen U, Bie P, Pedersen
EB, Jensen KT, Abildgaard U, et al.
Natriuretic peptides in the monitoring
of anthracycline induced reduction in
left ventricular ejection fraction. Eur
J Heart Fail 2005;7:87-93.
Gronlund B, Christensen IJ, Bulow-
Lehnsby AL, Engelholm SA, Hansen
HH, Hogdall C. Recurrent epithelial
ovarian cancer: validation and
improvement of an established
prognostic index. Eur J Obstet
Gyneco Repro Biol 2005;123:98-106.
Gronlund B, Engelholm SA, Horvath G,
Maenpaa J, Ridderheim M.
Sequential topotecan and oral
etoposide in recurrent ovarian
carcinoma pretreated with platinumtaxane.
Results from a multicenter
phase I/II study. Cancer
2005;103:1388-96.
Gronlund B, Lundvall L, Christensen IJ,
Knudsen JB, Hogdall C. Surgical
cytoreduction in recurrent ovarian
carcinoma in patients with complete
response to paclitaxel-platinum. Eur J
Surg Oncol 2005;31:67-73.
Hansen H. Lung Cancer-An update. Lung
Cancer 2005; 49(3):285-8.
Hutchings M, Loft A, Hansen M,
Pedersen LM, Buhl T, Jurlander J, et
al. FDG-PET after two cycles of
chemotherapy predicts treatment
failure and progression-free survival
in Hodgkin lymphoma. Blood
2006;107:52-9.
Lajer CB.; Daugaard S.; Hansen HS.;
Kirkegaard,J.; Holmgaard,S.;
Christensen,M.E. Soft tissue
sarcomas of the head and neck: a
single-centre experience. Clin
Otolaryngol 2005;30(2):176-182.
Langer SW, Thougaard AV, Sehested M,
Jensen PB. Treatment of
anthracycline extravasation in mice
with dexrazoxane with or without
DMSO and hydrocortisone. Cancer
Chemother Pharmacol 2006;57:125-
8.
Mouridsen HT, Bhatnagar AS. Letrozole
in the treatment of breast cancer.
Expert Opin Pharmacother
2005;6:1389-99.
Mouridsen HT, Robert NJ. Benefit with
aromatase inhibitors in the adjuvant
setting for postmenopausal women
with breast cancer. Med Gen Med
2005;7:20.
Mouridsen HT, Robert NJ. The role of
aromatase inhibitors as adjuvant
therapy for early breast cancer in
postmenopausal women. Eur J
Cancer 2005;41:1678-89.
Pappot H, Pedersen AN, Brunner N,
Christensen IJ. The complex between
urokinase (uPA) and its type-1
inhibitor (PAI-1) in pulmonary
adenocarcinoma: Relation to
prognosis. Lung Cancer 2006;51:193-
200.
Ryberg M, Nielsen D, Osterlind K,
Andersen PK, Skovsgaard T,
Dombernowsky P. Predictors of
central nervous system metastasis in
patients with metastatic breast cancer.
A competing risk analysis of 579
patients treated with epirubicin-based
chemotherapy. Breast Cancer Res
Treat 2005;91:217-25.
Stromgren AS, Sjogren P, Goldschmidt
D, Petersen MA, Pedersen L,
Hoermann L, et al. A longitudinal
study of palliative care: patientevaluated
outcome and impact of
attrition. Cancer 2005;1747-55.
B. Medforfatter fra forskningsenheden
Almasi CE, Hoyer-Hansen G, Christensen
IJ, Dano K, Pappot H. Prognostic
impact of liberated domain I of the
urokinase plasminogen activator
receptor in squamous cell lung cancer
tissue. Lung Cancer 2005;48:349-55.
Christensen HC, Schuz J, Kosteljanetz M,
Poulsen HS, Boice JD, Jr,
McLaughlin JK, et al. Cellular
telephones and risk for brain tumors:
a population-based, incident casecontrol
study. Neurology
2005;64:1189-95.
Franklin J, Paus M, Pluetschow A, Specht
L, Franklin J. Chemotherapy,
radiotherapy and combined modality
for Hodgkin's disease, with emphasis
on second cancer risk. Cochrane
Database Syst Rev 2005;CD003187.
Hill DA, Gilbert E, Dores GM,
Gospodarowicz M, van Leeuwen FE,
Holowaty E, et al. Breast cancer risk
following radiotherapy for Hodgkin
lymphoma: modification by other risk
factors. Blood 2005;106:3358-65.
Hoei-Hansen CE, Rajpert-De Meyts E,
Daugaard G, Skakkebaek NE.
Carcinoma in situ testis, the
progenitor of testicular germ cell
tumours: a clinical review. Ann
Oncol 2005;16:863-8.
Hoyer M, Roed H, Sengelov L, Traberg
A, Ohlhuis L, Pedersen J, et al.
Phase-II study on stereotactic
radiotherapy of locally advanced
pancreatic carcinoma. Radiother
Oncol 2005;76:48-53.
Knoop AS, Knudsen H, Balslev E,
Rasmussen BB, Overgaard J, Nielsen
KV, et al. retrospective analysis of
topoisomerase IIa amplifications and
deletions as predictive markers in
primary breast cancer patients
randomly assigned to
cyclophosphamide, methotrexate, and
fluorouracil or cyclophosphamide,
epirubicin, and fluorouracil: Danish
Breast Cancer Cooperative Group. J
Clin Oncol 2005;23:7483-90.
Korreman SS, Pedersen AN, Nottrup TJ,
Specht L, Nystrom H. Breathing
adapted radiotherapy for breast
cancer: comparison of free breathing
gating with the breath-hold
technique. Radiother Oncol
2005;76:311-8.
Lajer H, Kristensen M, Hansen HH,
Nielsen S, Frokiaer J, Ostergaard LF,
et al. Magnesium depletion enhances
cisplatin-induced nephrotoxicity.
Cancer Chemother Pharmacol
2005;56:535-42.
Lajer H, Kristensen M, Hansen HH,
Christensen S, Jonassen T, Daugaard
G. Magnesium and potassium
homeostasis during cisplatin
treatment. Cancer Chemother
Pharmacol 2005;55:231-6.
Larsen SS, Vilmann P, Krasnik M,
Dirksen A, Clementsen P, Maltbaek
N, et al. Endoscopic ultrasound
guided biopsy performed routinely in
lung cancer staging spares futile
thoracotomies: preliminary results
from a randomised clinical trial. Lung
Cancer 2005;49:377-85.
Nathanson KL, Kanetsky PA, Hawes R,
Vaughn DJ, Letrero R, Tucker K, et
al. The Y deletion gr/gr and
susceptibility to testicular germ cell
tumor. Am J Hum Genet
2005;77:1034-43.
Olsen AH, Njor SH, Vejborg I, Schwartz
W, Dalgaard P, Jensen MB, et al. A
model for determining the effect of
mammography service screening.
Acta Oncol 2005;44:120-8.
Pedersen MW, Pedersen N, Damstrup L,
Villingshoj M, Sonder SU, Rieneck
K, et al. Analysis of the epidermal
growth factor receptor specific
transcriptome: effect of receptor
expression level and an activating
32 Videnskabelig årsrappport